A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

NCT05326516 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Leukemias
Acute Lymphoblastic Leukemia
Acute Lymphocytic Leukemia
Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia
Acute Undifferentiated Leukemia

Interventions

DRUG: Revumenib
DRUG: Chemotherapy Regimen 1
DRUG: Chemotherapy Regimen 2

Sponsor

Syndax Pharmaceuticals